Linda T. Vahdat, MD, MBA, discusses the design of a phase 2 trial of copper depletion as a strategy to prevent metastasis in high-risk TNBC.
Linda Vahdat, MD, MBA
Advertisement
Linda Vahdat, MD, MBA, is section chief of Medical Oncology and interim section chief of Hematology at Dartmouth Health, as well as a professor of medicine at the Dartmouth College Geisel School of Medicine.
Articles by Linda Vahdat, MD, MBA
Linda T. Vahdat, MD, MBA, discusses the scientific rationale for therapeutic copper depletion to prevent triple-negative breast cancer metastasis.
Linda T. Vahdat, MD, MBA, discusses the rationale for depleting copper levels as a form of high-risk triple-negative breast cancer management.
Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.
Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
3
The OncFive: Top Oncology Articles for the Week of 7/19
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5